RxDoctor Payments Data

Michael Bagheri, MD

Cardiovascular Disease · Palm Springs, CANPI 1740463322

Payments from drug & device makers

$31,493in general payments, 2019–2025

Across 700 payments — averaging $44.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$17K
  • Abbott$3K
  • Novartis$1K
  • Boston Scientific$981
  • AstraZeneca$963
  • Johnson & Johnson$948
  • plus $7K from 39 others

What the payments were for

  • Speaking & faculty fees$16,56053%
  • Travel & lodging$2,1007%
  • Food & beverage$12,64240%
  • Education$1911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,493 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,534,276
Medicare patients
909
Services billed
24,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban869$878,174
EntrestoSacubitril/Valsartan353$371,568
JardianceEmpagliflozin283$259,126
XareltoRivaroxaban181$188,846
BrilintaTicagrelor227$185,442
FarxigaDapagliflozin Propanediol159$131,279
Repatha SureclickEvolocumab151$125,678
MultaqDronedarone Hcl79$105,053
Praluent PenAlirocumab29$26,399
VascepaIcosapent Ethyl55$22,221
Ezetimibe777$17,813
Metoprolol Succinate1,264$14,199
Repatha PushtronexEvolocumab17$13,553
Clonidine108$10,545
Rosuvastatin Calcium705$9,833

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$381$878,174869 claims
NovartisEntresto$1,450$371,568353 claims
AstraZenecaBrilinta, Farxiga$963$316,721386 claims
Boehringer IngelheimJardiance$481$259,126283 claims
Johnson & JohnsonXarelto$948$188,846181 claims
Sanofi-aventis U.S. LLCMultaq$325$105,05379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Palm Springs

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →